2007

BioAlliance Pharma Provides Information on a Press Release Received from Immtech Pharmaceuticals: Business Wire - December 26, 2007; PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) announces that it has just received the following press release from Immtech Pharmaceuticals, Inc. , the US company from which it has licensed the European rights for pafuramidine: NEW YORK, Dec. 26 -- Immtech Pharmaceuticals, Inc. (The Company
ISENTRESS(reg) (raltegravir) from MSD, First Integrase Inhibitor, Approved by the European Union Commission: First-in-Class Therapy Addresses Medical Need for New Treatment Options in Treatment-Experienced Patients: Business Wire - December 21, 2007; WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck Sharp & Dohme (MSD) announced today that ISENTRESS(reg) (raltegravir) has been granted a license from the European Union Commission (Commission) by way of a decision for use in combination with other antiretroviral medicinal products for the treatment of HIV-1 infect
Affymetrix Simplifies Copy Number Data Analysis for Association and Cytogenetic Studies: Business Wire - December 17, 2007; New Genotyping Console(TM) 2.0 Offers up to 10 Times the Sensitivity for Detecting Copy Number Changes Than Competing Platforms SANTA CLARA, Calif. -- Affymetrix Inc. (Nasdaq:AFFX) today announced the availability of its Genotyping Console(TM) 2.0 (GTC 2.0) Software, an easy-to-use analysis tool for determining single
Baseball Bombshell Lesson: Illegal Steroid Use Dangerous to Young Athletes - Hanley Center reports serious consequences: Business Wire - December 17, 2007; WEST PALM BEACH, Fla. -- The widespread use of anabolic steroids by pro baseball players that was revealed in former Senator George Mitchell s bombshell report begs the question of role models and player s influence on young athletes. Many teenagers don t know the risks of performance enhancing drugs, but do understand
European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection: Business Wire - December 17, 2007; Product Developed Through Joint Venture Between Bristol-Myers Squibb and Gilead Sciences , the First of Its Kind in HIV Treatment PRINCETON, N.J. & FOSTER CITY, Calif. -- The European Commission has granted marketing authorization for ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/
Remarks by President Bush and President Yar'adua of the Federal Republic of Nigeria in Photo Opportunity: Business Wire - December 13, 2007; WASHINGTON -- Oval Office, 10:50 A.M. EST PRESIDENT BUSH: Mr. President, it s been my honor to welcome you here to the White House. We just had a very extensive and fruitful discussion on a variety of issues, and that s what you would expect when friends meet together. The President is committed to democracy and rule o
PRI Receives Bill & Melinda Gates Foundation Grant to Elevate Global Health and Global Development Coverage in Public Media: Business Wire - December 12, 2007; MINNEAPOLIS--(BUSINESS WIRE)--Public Radio International (PRI) announces that it has received a three-year, $5 million grant from the Bill & Melinda Gates Foundation to lead an unprecedented effort to produce and distribute global health and development content. By creating an array of penetrating journalism for us
Interactive Intelligence CEO Makes Largest Private Donation to Nobel Prize-Nominated AIDS Program: Dr. Donald E. Brown Donates $1 Million in Stock to the Indiana University-Kenya Partnership: Business Wire - December 11, 2007; INDIANAPOLIS -- Interactive Intelligence (Nasdaq:ININ) CEO, Dr. Donald E. Brown, has donated $1 million in stock to the Indiana University- Kenya Partnership, a program designed to prevent and treat HIV/AIDS. This is the single largest private donation since the program s inception. The Partnership began in 1989 whe
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe: Business Wire - December 11, 2007; PRINCETON, N.J. & FOSTER CITY, Calif. -- Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences , Inc. (Nasdaq:GILD) today announced an agreement to commercialize ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Europe for the treatme
Humana Extends Agreements with LabCorp and Quest Diagnostics: New Contract for National Laboratory and Testing Services: Business Wire - December 10, 2007; LOUISVILLE, Ky. -- Humana Inc. (NYSE: HUM) announced today that it has signed multi-year agreements with Laboratory Corporation of America(R) Holdings (NYSE: LH) and Quest Diagnostics (NYSE: DGX), extending current contracts that provide laboratory and testing services for Humana members. The agreements are effective J
Panacos Announces Results of Bevirimat 350 mg Cohort, Data Support Further Dose Escalation in Phase 2b Study - Company to Hold a Conference Call at 5:00 p.m. EST Today: Business Wire - December 10, 2007; WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced preliminary results from the 350 mg cohort of a Phase 2b study of bevirimat (PA-457) in patients failing HIV therapy due to drug resista
Trimeris Announces 2008 Strategic Plan: The Strategic Plan is Designed to Maximize Cash Flows from FUZEON(R), While Also Advancing TRI-1144 to a Value-Creating Milestone - Research and Development Functions to be Eliminated: Business Wire - December 10, 2007; MORRISVILLE, N.C. -- Trimeris, Inc. (NASDAQ: TRMS) today announced its strategic plan for 2008 that is designed to maximize cash flows from FUZEON while also advancing TRI-1144 to a value-creating milestone. The Company plans to file an Investigational New Drug application ( IND ) for TRI-1144, the Company s next-gener
Targacept to Receive $6 Million from GlaxoSmithKline for Initiation of Phase I Trial of Neuropathic Pain Candidate: Business Wire - December 10, 2007; WINSTON-SALEM, N.C. -- Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that it has initiated a Phase I clinical trial of its product candidate TC-6499. The initiation of the trial triggers a $6.0 million milestone
Cookshow.com Announces Strategic Partnership for Corporate Giving with Project Concern International: Business Wire - December 10, 2007; PARIS -- Cookshow.com, the first 100% video-sharing community exclusively on the niche of cooking, announced today that it has formed a strategic partnership with the corporate giving program of Project Concern International (www.projectconcern.org). The company will donate a fixed amount of (euros)10 ($14) for each re
Press Briefing by Dana Perino: Business Wire - December 6, 2007; WASHINGTON -- James S. Brady Press Briefing Room 12:30 P.M. EST MS. PERINO: Hi, everybody. Just a quick comment. The President, as you know, at 1:40 p.m., is going to make a statement after getting a briefing from Secretaries Paulson and Jackson on housing. In August, the President proposed legislative reforms to assis
Roche Diagnostics, a World Leader in HIV Monitoring Tests, and ARK Diagnostics, Inc. Sign Letter of Intent to Commercialize ARK's HIV Drug Monitoring Products: Business Wire - December 6, 2007; SUNNYVALE, Calif.--(BUSINESS WIRE)--ARK Diagnostics, Inc. ( ARK ), and Roche Diagnostics signed a letter of intent to negotiate a collaboration agreement that would grant Roche distribution and commercialization rights for ARK s anti-HIV drug monitoring products. We are pleased to partner with Roche Diagnostics - a wor
Swarmcast and iClips.net Stream Nelson Mandela's 46664 World AIDS Day Concert: Business Wire - December 5, 2007; iClips uses Swarmcast Live to stream high-quality video to global audience MINNEAPOLIS--(BUSINESS WIRE)--Swarmcast, the leader in high-quality online video delivery, and iClips.net, the leading provider of free online concert streams, recently teamed together to provide a live Internet broadcast from Nelson Mandela s 4
BioAlliance Pharma Acquires the European Commercialization Rights to Pafuramidine for the Treatment of Pneumocystis Carinii Pneumonia: Business Wire - December 5, 2007; Building a Consistent Product Portfolio in Opportunistic Infections in Cancer And AIDS Patients BioAlliance Pharma to Host a Conference Call Today At 11.30 AM CET Paris Time (10.30 AM GMT, London Time) PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris - ticker code BIO), today announced tha
Creation of the Swiss Institute for Vaccine Research in Lausanne, Switzerland: Business Wire - December 5, 2007; LAUSANNE, Switzerland--(BUSINESS WIRE)--The Swiss Institute for Vaccine Research will be launched on December 5, 2007, in Lausanne, Switzerland. The new Institute will encompass the principal aspects of vaccine research to fight the three main infectious diseases: HIV/AIDS, tuberculosis and malaria. The Institute will
Global Personalities and 46664 Support First Socially-Conscious Online TV Network - t5m.com: Business Wire - December 3, 2007; James Blunt, Kate Bosworth, Ray Winstone, Christian Slater and Nelson Mandela s HIV/AIDS charity, 46664, Support New Online Network LOS ANGELES & LONDON--(BUSINESS WIRE)--t5m today announced the first socially-conscious, online TV network, whose mission is to inspire and entertain - www.t5m.com. t5m gives users dir
Canopus BioPharma Selected to Present its Drug Candidate for HIV/AIDS Treatment at the Global Summit on AIDS and the Church: Business Wire - December 3, 2007; Canopus President Speaks Among Presidential Candidate and New York Senator Hillary Clinton and Other World and Industry Leaders Global Summit on AIDS and the Church LOS ANGELES--(BUSINESS WIRE)--Canopus BioPharma, Inc. (OTCPK:CBIA), a biotechnology company developing pharmaceutical products and assay methods for patien
Calypte Recognizes World AIDS Day with Product Donation: Second Donation in Kenya: Business Wire - December 3, 2007; PORTLAND, Ore.--(Business Wire)--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that, in honor of World AIDS Day, it has donated 4,000 Aware(TM) HIV-1/2 OMT (oral fluid) tests to the National AIDS Control Council (NACC) of the Republic of
MEDIA ALERT: Fifth Anniversary for Annual Roche AIDS Walk: Business Wire - November 30, 2007; More than 900 Employees Volunteer to Raise Funds in NJ --(BUSINESS WIRE)--Roche WHAT: Opportunity to speak with NJ patients and volunteers. More than 900 local Roche employees have volunteered to participate in the fifth annual Global Roche Employee AIDS Walk today to raise funds to support children infected and affect
Press Briefing by Dana Perino and Mark Dybul, U.S. Global AIDS Coordinator: Business Wire - November 30, 2007; WASHINGTON--(BUSINESS WIRE)--James S. Brady Briefing Room 1:40 P.M. EST MS. PERINO: It s been our great pleasure to work with Kelly O Donnell of NBC News. And today is her last day covering the White House full-time, and so we wish you the very best in your -- (applause.) MS. O DONNELL: Thank you. MS. PERINO: Maybe you
t5m.com Brings Fans Backstage at 46664 World Aids Day Concert: Business Wire - November 30, 2007; Online TV network to deliver behind-the-scenes coverage of World Aids Day Concert, featuring artists Peter Gabriel, Annie Lennox, Corinne Bailey Rae, Razorlight, Ludacris, Goo Goo Dolls and Jamelia CAPE TOWN, South africa & LOS ANGELES & LONDON--(BUSINESS WIRE)--t5m.com, the first socially-conscious online TV n
World AIDS Day Kicks Off in Los Angeles with Breakfast and Commemorative Balloon Launch on Saturday, Dec. 1: Business Wire - November 30, 2007; --(BUSINESS WIRE)--Office AIDS Programs and Policy: WHAT: The County of Los Angeles, Department of Public Health, Office of AIDS Programs and Policy, will recognize government officials, public health leaders and HIV/AIDS community representatives in an awards ceremony and breakfast commemoration of World AIDS Day on D
AIDSWATCH, a 24-hour World AIDS Day Memorial Cablecast Will Air Live from West Hollywood on Saturday, December 1, 2007: Business Wire - November 30, 2007; City of West Hollywood: WHAT: On World AIDS Day, Saturday, December 1, 2007, the City of West Hollywood will once again sponsor and originate AIDSWATCH, an electronic, televised memorial. AIDSWATCH is in its 11th year. For 24 hours beginning at midnight, West Hollywood Citychannel 10 (on Time Warner Cable) will display
President And Mrs. Bush Reaffirm Our Nation's Unprecedented Commitment To Fighting HIV/AIDS At Home And Abroad: Business Wire - November 30, 2007; WASHINGTON -- Office of the Press Secretary - World AIDS Day 2007 Today, President and Mrs. Bush will mark World AIDS Day 2007 by participating in a faith-based roundtable discussion at Calvary United Methodist Church in Mount Airy, Maryland. Since 2001, the Administration has delivered more than $129 billion to fight
Avexa's ATC Demonstrates Activity Against Emerging Class Resistance: Business Wire - November 30, 2007; MELBOURNE, Australia -- Biotechnology company Avexa Limited (ASX:AVX) announced today that a series of in-vitro experiments have shown that ATC maintains potent antiviral activity against strains of HIV which are resistant to the new class of integrase inhibitors, including the recently approved Merck HIV integrase inh
Kaiser Permanente Announces $1.3 Million in Grants for HIV/AIDS Services: World AIDS Day Underscores Long-Term Commitment To Community Partnerships: Business Wire - November 30, 2007; PASADENA, Calif. -- Kaiser Permanente recently announced more than $1.3 million in statewide community benefit grants to help 74 organizations promote HIV/AIDS awareness, prevention, screening, support and treatment for people living with the disease. The individual grants were made throughout 2007 and were given to no
Florida College Football Powerhouses Team Up on World AIDS Day to Help KOOL Kids Youth Group Tackle HIV and AIDS: Business Wire - November 30, 2007; Florida State University Head Coach Bobby Bowden and University of Miami Head Coach Randy Shannon Join Forces to Support Through Their Eyes Photographic Exhibit Created by Young Adults Born with HIV/AIDS Florida Department of Health Partners with FSU and the Green Family Health Initiative at University of Miami to Tran
Remarks by the President on World AIDS Day: Business Wire - November 30, 2007; MOUNT AIRY, Md. -- Calvary United Methodist Church 11:43 A.M. EST THE PRESIDENT: Tomorrow is World AIDS Day, and Laura and I are honored to commemorate the occasion here at the Calvary United Methodist Church. And we re honored to commemorate the day with people who have dedicated their lives to save lives. I want to
OraSure Technologies Supports Global and Domestic Rapid HIV Testing Initiatives for World AIDS Day: OraSure to Participate in NASDAQ Market Open and HIV/AIDS Industry Panel Discussion on November 30, 2007: Business Wire - November 29, 2007; BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced its support of more than 150 global and domestic rapid HIV testing initiatives in recognition of World AIDS Day, commemorated annually on December 1st. OraSure s support of these initiatives, taking
Inhibitex Announces Appointment of New Scientific Advisory Board: Recognized Thought Leaders to Advise Company on Promising Antiviral Pipeline: Business Wire - November 29, 2007; ATLANTA -- Inhibitex, Inc. (Nasdaq: INHX) today announced it has established a new scientific advisory board to provide the Company with scientific and clinical guidance on its ongoing research and development activities. The Company s scientific advisory board is composed of distinguished scientists and thought leader
Minnesota AIDS Project Introduces 25 Years/25 Stories Campaign on World AIDS Day 2007: Business Wire - November 29, 2007; MINNEAPOLIS -- The Minnesota AIDS Project announced today that it will kick off a new campaign to recognize important stories and leaders in the last 25 years of fighting HIV in Minnesota. The campaign, titled 25 Years/25 Stories, will launch on World AIDS Day 2007 (December 1) with the story of the first case of HIV i
Language Line Services Introduces "Relating in Red" AIDS Awareness Dual-Handset Telephone to Help Fight AIDS in 175 Languages: Fundraising Program to Benefit the Elizabeth Glaser Pediatric AIDS Foundation, Broadway Cares/Equity Fights AIDS, and AIDS Education Global Information System: Business Wire - November 29, 2007; MONTEREY, Calif. -- In observance of World AIDS Day (December 1, 2007), Language Line Services, the leading provider of language solutions, has announced the introduction of the Relating in Red AIDS awareness dual-handset phone program. As part of this fundraising program for HIV/AIDS awareness, health care providers w
BioAlliance Pharma Accelerates Its International Clinical Research Program: Extension to the United States of the acyclovir Lauriad(R) Phase III Trial: Business Wire - November 28, 2007; PARIS -- Regulatory News: BioAlliance Pharma SA (Paris:BIO) today announced it has extended its ongoing acyclovir Lauriad(R) Phase III trial in the treatment of oral herpes to the United States . Ten clinical centers have been opened in the country and will join the forty or so in Australi
MOTIVATE Continues Its Work With the Ministry of Health of the Socialist Republic of Vietnam: MOU Signed With the AIDS Committee Ho Chi Minh City: Business Wire - November 27, 2007; OAKLAND, Calif. -- MOTIVATE -- a global partnership between Ramsell and Sojitz -- and the Ministry of Health of the Socialist Republic of Vietnam , AIDS Committee Ho Chi Minh City sign a Memorandum of Understanding (MOU) setting up the fundamental principles for the collaboration between the AIDS Committee Ho Chi Minh
Inovio Biomedical Partner Tripep Treats First Subject in Phase I/II Study of Novel Hepatitis C DNA Vaccine: Greatly Enhanced Results Using Inovio's Electroporation Delivery Technology with DNA-based Therapeutic Vaccine Leads to First Treatment in HCV Human Trial: Business Wire - November 29, 2007; SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB of Sweden , treated the first subject in a Phase I/II clinical trial of a novel DNA vaccine designed to treat chronically infe
Allion Healthcare, Inc. to Present at the Piper Jaffray 19th Annual Health Care Conference: Business Wire - November 26, 2007; MELVILLE, N.Y. -- Allion Healthcare, Inc. (NASDAQ: ALLI), a national provider of specialty pharmacy and disease management services focused on HIV/AIDS patients, announced today it will participate in the Piper Jaffray 19th Annual Health Care Conference in New York City at the The Pierre hotel, November 27th through No
Pharmaceutical Firm ARTEC, Inc.� Announces Production of TUBERCIN� for Selected Uses in South Africa and the Bahamas - Shareholders Follow-Up Report: Business Wire - November 26, 2007; OKLAHOMA CITY -- Production of TUBERCIN�, a revolutionary polysaccharide compound to be used as an HIV/AIDS and ANTI-CANCER immunostimulant, has begun with the focus on South Africa and the Bahamas as mission delivery sites, announces Mr. Gerry Knight, Executive Vice President of ARTEC, Inc.� (Pink Sheets:ATKJ).
Penn Libraries to Display Panel of the Nobel Prize Nominated AIDS Memorial Quilt: Business Wire - November 26, 2007; PHILADELPHIA -- The Penn Libraries, in partnership with the University of Pennsylvania s Lesbian Gay Bisexual Transgender Center, and other campus agencies, will commemorate the 20th anniversary of the AIDS Memorial Quilt, internationally recognized as a symbol of personal and universal grief, remembrance, and healing
Avexa Gets 'green light' for ATC Phase III Program: Business Wire - November 20, 2007; MELBOURNE, Australia -- Avexa (ASX:AVX) announced at its Annual General Meeting (AGM) today that it has received positive feedback from both North American and European regulatory authorities allowing immediate progression into a Phase III program for apricitabine (ATC), an NRTi the company is developing for the treatm
South African AIDS Novel Named a Booksense Notable for January 2008: Business Wire - November 19, 2007; LOS ANGELES -- FATHER MICHAEL S LOTTERY: A NOVEL OF AFRICA by Johan Steyn, a debut novel concerning the AIDS crisis in Southern Africa, has just been named a Booksense Notable for January 2008, according to the publisher Schaffner Press, Inc. of Tucson, Az. The Booksense endorsement is the latest accolade bestowed upon
African Red Tea Imports Announces Availability of Organic Anti-Depressant and Immune Support Remedies from South Africa: Medical Professionals and Health Conscious Consumers Tout Efficacy of New Herbal Remedies: Business Wire - November 19, 2007; LOS ANGELES -- African Red Tea Imports (ART) is pleased to announce the addition of two major new products to their outstanding line of Rooibos based organic and kosher products. Sutherlandia Frutescens, known in South Africa as Cancer Bush, and Sceletium Tortuosum, a plant with recorded usage dating back to the 1600s,
The Aethlon Hemopurifier(R) Reverses Immune Suppression in Cancer: Business Wire - November 19, 2007; SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, announced today that researchers have documented the Aethlon Hemopurifier(R) is able to remove the immunosuppressive activity normally found in the fluid of cancer patients. Aethlon recently discovered
Nutra Pharma Announces Publication of Test Kit Technology in the International Journal of TB and Lung Diseases: Business Wire - November 19, 2007; BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis(MS), has today announced that its wholly owned subsidiary, Designer Diagnostics, Inc., will be featured in an upcoming article published in the International Journal of TB and Lung Diseas
BioAlliance Pharma Completes Patient Enrolment Ahead of Schedule for Its Pivotal Phase III Clinical Trial of Loramyc(R) in The USA for the Treatment of Oropharyngeal Candidiasis: Business Wire - November 16, 2007; PARIS -- Regulatory News: BioAlliance Pharma SA (Paris:BIO), today announced that it had successfully completed patient enrolment in the pivotal phase III clinical trial performed with a view to registering Loramyc(R) in the US, for the treatment of oropharyngeal candidiasis. With 540 patients enrolled by 40 specialist
The Research 'Stakeholder Insight: HIV Therapy Dynamics' Shows That the Top 5 Most Popular Regimens Selected by Physicians Account for Only 13% of Patients in Salvage Therapy: Business Wire- November 16, 2007; DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reports/c74552) has announced the addition of Stakeholder Insight: HIV Therapy Dynamics to their offering. Introduction Despite several developments in efforts to tackle the spread of HIV, the total number of people living with HI
Inovio Biomedical to Present DNA Vaccine Overview at Scientific Meeting: Business Wire - November 14, 2007; SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced that Dr. Michael Fons, Vice President, Corporate Development, has been invited to present an overview of the company s technology and products at the 2007 Annua
Aethlon Medical Announces HIV-AIDS Research Collaboration: Business Wire - November 14, 2007; SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, announced today it has initiated a research collaboration to study the in vitro effectiveness of the Aethlon Hemopurifier(R) to clear the Human Immunodeficiency Virus (HIV) from blood. The studies are b
STEP Study Volunteers to be Informed Whether They Received Vaccine or Placebo: Business Wire - November 13, 2007; SEATTLE -- Merck & Co. , Inc. and the HIV Vaccine Trials Network (HVTN) today announced that study volunteers in the STEP study of Merck s HIV vaccine (V520) will be told whether they received vaccine or placebo, and all study volunteers will be encouraged to continue to return to their study sites on a regular bas
UnBuenDoctor(R) Launches the First Ever Spanish-Language Website Dedicated to Providing Hispanics with the Ultimate Resources for Health Care: UnBuenDoctor.com Gives Hispanics the Tools They Need to Have Information about Their Health, Doctors, Organizations, Insurance and Benefits at the Click of a Button: Business Wire - November 13, 2007; CHICAGO -- UnBuenDoctor(R) has launched the first Spanish-language website that will focus on the 32.2 million Spanish speakers in the US and allow them to search for doctors and organizations while obtaining the latest information about their health, beauty, nutrition and diverse well-being issues that prevail through
Bioalliance Pharma Announces Its Participation in the Natixis Securities Midcap Healthcare Conference: Business Wire - November 12, 2007; The Natixis Securities MidCap Healthcare Conference PARIS, France Regulatory News: BioAlliance Pharma SA (Paris:BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics which address resistance issues in cancer, HIV and opportunistic infections, today announced that i
Educational Documentary to Inform Public of Cross-Border Health Issues: Business Wire - November 8, 2007; SAN DIEGO -- In response to the lack of knowledge regarding cross-border health, the International Community Foundation and Fundacion International de la Comunidad A.C. are providing an educational documentary to help inform San Diegans about critical health issues affecting both sides of the border. San Diegans are fa
TB Alliance Advances Two Drugs in Clinical Trials on Path to Faster, Better Tuberculosis Treatments: Trailblazing Phase III Trial Seeks to Shorten TB Treatment - Novel Candidate in Phase II Offers Hope for More Effective, Simpler Cure: Business Wire - November 8, 2007; NEW YORK & CAPE TOWN, South Africa -- The Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership accelerating the discovery and development of new drugs to fight tuberculosis (TB), today announced the advancement of two promising TB treatment candidates into the nex
Nutra Pharma Announces Designer Diagnostics Test Kit Technology to Be Presented at International Lung Health Conference: Business Wire - November 8, 2007; 38th Union World Conference on Lung Health BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS), has today announced that leading NonTuberculous Mycobacterium (NTM) research scientist, Dr. Rahul Narang, will be showcasing the Designer
Data from STEP Study Presented at Open Scientific Session Confirm Merck's Investigational HIV Vaccine was not Effective: Business Wire - November 7, 2007; SEATTLE -- In the STEP study, one of two phase II trials of Merck & Co. , Inc. s investigational HIV vaccine (V520), the vaccine was not effective at either preventing infection in volunteers not previously infected with HIV or at reducing viral loads in those study volunteers who became infected with HIV during th
JHG-Townsend Recognized as PR News' Non-Profit PR Award Finalist for Outstanding Work Contributed to Diana Legacy Fund Launch: Successful Public Relations Campaign Acknowledged in Event PR Category for Work with Organizations Providing HIV/AIDS Hospice and Palliative Care in Sub-Saharan Africa: Business Wire - November 7, 2007; SAN DIEGO -- JHG-Townsend, a results-driven communications group that effectively combines traditional marketing and PR services with new digital media, today announced it has been named as a finalist in the Event PR category for PR News prestigious Non-Profit PR Awards. The public relations campaign was designed to la
American India Foundation To Honor Aethlon Medical CEO: Business Wire - November 7, 2007; SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, disclosed today that its Chairman and CEO, James A. Joyce, will be presented the Spirit of India award at the America India Foundation (AIF) annual gala on December 1, 2007. The event, sponsored by the
Metastatix Granted Investigational New Drug (IND) Application for MSX-122: First IND Submitted by Metastatix Targets Cancer: Business Wire - November 6, 2007; ATLANTA -- Metastatix, Inc., an emerging pharmaceutical company focused on the development of small molecule therapeutics, announced today that the U.S. Food and Drug Administration ( FDA ) has accepted its Investigational New Drug (IND) application for MSX-122, a potent CXCR4 inhibitor that the company is developing f
Bill Gates and Nathan Myhrvold to Keynote Institute for Systems Biology's 2008 Annual Symposium: 7th Annual Institute for Systems Biology International Symposium: Business Wire - November 5, 2007; SEATTLE -- The Institute for Systems Biology announces that Bill Gates, co-chair of the Bill & Melinda Gates Foundation and chairman of Microsoft Corporation and Nathan Myhrvold, PhD, president and CEO of Intellectual Ventures, will serve as keynote speakers for the 7th Annual Institute for Systems Biology Internat
Guardian Announces Landmark Joint Development Agreement with Internationally Renowned Aurum Institute: Agreement to Accelerate Development and Distribution of Breakthrough Imaging Systems to Decelerate Tuberculosis and Malaria Epidemics in Developing Nations: Business Wire - November 5, 2007; Key Highlights of Aurum Agreement: * Guardian s Signature Mapping technology to potentially save thousands of lives with early detection of TB bacteria and Malaria parasites * Guardian to raise visibility in worldwide healthcare community * Aurum to provide access to critical expertise and clinical case studies for tar
Instead Patents New Vaginal Applicator for Use with Amphora(trademark): Product Facilitates Use of Personal Lubricant and Candidate Microbicide: Business Wire - November 5, 2007; LA JOLLA, Calif.--(BUSINESS WIRE)--Instead Inc., developer of over-the-counter women s reproductive health products, has patented a new reusable showerhead vaginal applicator, which it plans to distribute with its FDA-cleared personal vaginal lubricant and candidate microbicide, Amphora. Designed to be more comfortable
Gilead Announces 48-Week Data from Two Pivotal Phase III Studies Evaluating Viread(R) For the Treatment of Chronic Hepatitis B -- Detailed Results From Studies 102 and 103 Presented at The Liver Meeting 2007 --: Business Wire - November 2, 2007; BOSTON -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced the presentation of detailed 48-week data from two phase III pivotal clinical trials, Studies 102 and 103, which evaluate the safety and efficacy of once-daily Viread (R) ( tenofovir di
Aethlon Medical Initiates Human Clinical Studies: Business Wire - November 01, 2007; SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, announced today that it has initiated clinical testing the Aethlon Hemopurifier(R) in human studies being conducted at the Fortis Hospital in Delhi, India . The study, approved by the Ethics Committee f
Aethlon Medical to Present at BIOCOM 2007: Business Wire - October 30, 2007; BIOCOM 2007 SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing medical devices to treat infectious disease, is scheduled to give a presentation this Friday, November 2nd at the BIOCOM Investor Conference 2007. Aethlon Chairman and CEO, James A. Joyce will provide an overview of the company, includ
Inovio Biomedical's DNA Vaccine Delivery Technology Moves Ahead in Clinical Trial for Hepatitis C: Business Wire - October 30, 2007; SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB of Sweden , has begun enrolling patients for its Phase I/II clinical study of a novel DNA vaccine designed to treat chronicall
Panacos to Present at CIBC Healthcare Conference: Business Wire - October 30, 2007; WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, will present at the CIBC World Markets 18th Annual Healthcare Conference to be held from November 5-7, 2007 at the Waldorf-Astoria Hotel in New York, NY
Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients -- Results From Phase III 'SWEET' Study Presented at the 11th European AIDS Conference --: Business Wire - October 29, 2007; 11th European AIDS Conference (EACS) FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced 48-week data from a Phase III clinical trial evaluating virologically-suppressed patients with HIV who switched from treatment with twice-daily Combivir (R) (lamivu
City of West Hollywood, HANSON and TOMS Shoes Will Join Together to Fight Poverty and HIV/AIDS in Africa on Tuesday, October 30, 2007: News Conference to Take Place at West Hollywood City Hall at 10 a.m.: Business Wire - October 25, 2007; City of West Hollywood: WHAT: The City of West Hollywood, recording artists HANSON and TOMS Shoes will join together to help fight poverty and HIV/AIDS in Africa. The partnership is a component of the City s Global AIDS Initiative which was created with the goal of advocating for and supporting education, outreach and
HANSON and Blake Mycoskie, Creator of TOMS Shoes, to be Honored at the World-Famous West Hollywood Halloween Carnaval on Wednesday, October 31, 2007: Frighteningly Fabulous Entertainment to Include Thelma Houston, Klymaxx and Mini KISS: Business Wire - October 25, 2007; WEST HOLLYWOOD, Calif. -- The heart of West Hollywood, Santa Monica Boulevard, will once again be pulsing with excitement on Halloween night as hundreds of thousands of Halloween revelers are expected to flock to the famous Boulevard for the 2007 West Hollywood Halloween Costume Carnaval on Wednesday, October 31, 2007
Final Gemini Study Results Confirm Boosted Invirase Was as Effective as Kaletra While Providing an Improved Triglyceride Profile for HIV Patients -- 48-week results from head-to-head trial between boosted Invirase and boosted lopinavir presented for first time --: Business Wire - October 25, 2007; NUTLEY, N.J. -- Final 48-week results from an international head-to-head trial, presented today at the 11th European AIDS Conference (EACS), Madrid, demonstrated that treatment-naive HIV patients treated with the protease inhibitor Invirase (R) 500mg tablets (saquinavir mesylate), boosted with
Gilead Announces New LetairisTM (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1): Business Wire - October 23, 2007; -- Long-Term Data and Integrated Subgroup Analysis in Patients with Idiopathic PAH and PAH Associated with Connective Tissue Disease Presented at the Annual Meeting of the American College of Chest Physicians -- CHICAGO -- Gilead Sciences , Inc. (Nasdaq: GILD) today announced the presentation of new data from the Phase
YourTechOnline.com Leads Effort to Provide Technical Support for HIV/AIDS Treatment and Prevention in Africa: Business Wire - October 23, 2007; KELOWNA, British Columbia -- YourTechOnline.com Inc, PC Magazine Editors Choice award-winning provider of 24-hour-a-day online technical support, announces its plan to bring technical support and infrastructure advancement to the HIV/AIDS relief and child education crisis in Africa. The first organizations to be suppor
Prolacta Bioscience Processes 55,000 Ounces of Donor Breast Milk for International Breast Milk Project Shipment to South Africa: Quick International Donates Shipping Service from U.S. to South Africa: Business Wire - October 22, 2007; MONROVIA, Calif. -- Prolacta Bioscience, a privately held company that offers the first and only milk fortifier made from 100% human milk for the nutritional needs of premature and critically ill infants, announced the donated processing of over 50,000 ounces of milk for the International Breast Milk Project (IBMP). Th
City of West Hollywood, HANSON and Tom's Shoes Will Join Together to Fight Poverty and HIV/AIDS in Africa on Tuesday, October 30, 2007 - News Conference to Take Place at West Hollywood City Hall at 10 a.m.: Business Wire - October 19, 2007; WEST HOLLYWOOD, Calif. -- The City of West Hollywood, recording artists HANSON and TOMS Shoes will join together to help fight poverty and HIV/AIDS in Africa. The partnership is a component of the City s Global AIDS Initiative which was created with the goal of advocating for and supporting education, outreach and fund
GenVec Receives Additional Funding for 7th Year of HIV Vaccine Program: Business Wire - October 19, 2007; GAITHERSBURG, Md. -- GenVec, Inc. (Nasdaq:GNVC) announced today that the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has executed its sixth option period (year seven) under its multi-year collaboration with GenVec t
Remarks by the First Lady in a Tribute Speech at Africare Dinner for Her Excellency Ellen Johnson-Sirleaf: Business Wire - October 19, 2007; WASHINGTON -- Hilton Washington Washington, D.C. October 18, 2007 8:57 P.M. EDT MRS. BUSH: Thank you, Charlayne. Thank you, everyone. Thank you very, very much, Charlayne. Her Excellency, Ellen Johnson-Sirleaf, President of Liberia , it s great to have this opportunity to be with you. I m thrilled to have the chance to
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) -- Once Granted by the European Commission, ATRIPLA Would Represent the First And Only Once-Daily Single Tablet Regimen for Many HIV/AIDS Patients in the European Union --: Business Wire - October 18, 2007; PRINCETON, N.J. & FOSTER CITY, Calif. & WHITEHOUSE STATION, N.J. -- Bristol-Myers Squibb Company (NYSE:BMY), Gilead Sciences , Inc. (Nasdaq:GILD) and Merck & Co. , Inc. (NYSE:MRK) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issue
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV - Product Developed Through Joint Venture Between Bristol-Myers Squibb Company and Gilead Sciences, the First of Its Kind in HIV Treatment: Business Wire - October 17, 2007; PRINCETON, N.J. & FOSTER CITY, Calif. -- Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences , Inc. (Nasdaq:GILD) announced today that Health Canada has approved ATRIPLA(R) ( efavirenz 600 mg/emtricitabine 200 mg/
U.S. Doctors for Africa Launches Ghana Mobile Clinic Project as First Step in Proposed $70 Million Mobile Clinic Initiative: Business Wire - October 16, 2007; LOS ANGELES -- U.S. Doctors for Africa (USDFA) (www.usdfa.org) announces the Ghana Mobile Clinic Project-the deployment of its first mobile clinic to Africa. This is the first clinic of an anticipated 200 mobile clinics USDFA has committed to deploy by 2015 as part of its Mobile Clinic Initiative, a commitment made by
Leukocyte Reduction Seen as Significant Advance in Transfusion Medicine, Experts Urge Universal Adoption: Evidence of Risk Reduction of Current and Emerging Infections: Business Wire - October 15, 2007; EAST HILLS, N.Y. -- Experts called on government and medical organizations involved in blood transfusion to reverse one of the most serious public health policy errors in the history of transfusion therapy in the United States . Neil Blumberg, M.D. and Joanna M. Heal, M.D., specialists in transfusion medicine and hemat
Congresswoman Helps Cause by Getting Tested for HIV for National Latino AIDS Awareness Day Event and Official Launch of Test for Life Florida Coalition: Free Testing Will Be Available to Attendees - Monday, October 15, 2007 - 11:00 a.m. to 12:00 p.m.: Business Wire - October 15, 2007; Test for Life: WHO: Congresswoman Ileana Ros-Lehtinen to take HIV test to mark National Latino AIDS Awareness Day Panel Members: -- Alberto Santana: Office of HIV/AIDS/TB, Miami-Dade County Health Department -- Manuel Laureano-Vega M.S.,M.D.: Founder and Executive Director of Liga Contra Sida -- Maria G. Rodriguez, MD,
IndieMV Announces Official www.IndieMV.com Website Launch as Company Partners With UNICEF for Upcoming, Star-Studded, 'Unite Against AIDS' Benefit Concert: Avril Lavigne, Sarah McLachlan and Others to Perform at UNICEF AIDS Benefit Concert as IndieMV Provides Music-Video Based Contests to Promote Awareness: Business Wire - October 15, 2007; NEW YORK & LOS ANGELES -- IndieMV Media Group Inc. and associated Companies (Jake s Trucking International Inc. (OTCBB:JKTI)) announced today the official launch of the Company s web property www.IndieMV.com and shared details about their recent partnership with UNICEF to provide music-video based contests surround
UPDATE: FDA Approves ISENTRESS(TM) (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor: Business Wire - October 15, 2007; WHITEHOUSE STATION, N.J. -- Merck & Co. , Inc., announced Friday that the U.S. Food and Drug Administration ( FDA ) granted ISENTRESS(TM) (raltegravir) tablets accelerated approval for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients wh
Statement by the Press Secretary: President Bush to Meet with Ugandan President Museveni: Business Wire - October 12, 2007; MIAMI -- President Bush will welcome President Yoweri Museveni of the Republic of Uganda to the White House on October 30, 2007. The President and President Museveni will discuss Uganda s leadership in Somalia , the Lord s Resistance Army, and President Museveni s development plan for northern Uganda, as well as their
Gilead Submits Marketing Applications in the United States and European Union for Viread(R) (Tenofovir Disoproxil Fumarate) for the Treatment of Chronic Hepatitis B: Business Wire - October 11, 2007; FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq: GILD) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration ( FDA ) and a Type II variation to the European Medicines Agency (EMEA) for marketing approval of
OraSure Technologies and the Latino Commission on AIDS Launch HIV Testing Initiative in Recognition of National Latino AIDS Awareness Day, October 15, 2007: Congressional Hispanic Caucus Joins Effort to Help Latinos Learn Their HIV Status: Business Wire - October 10, 2007; BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced the launch of a Rapid HIV Testing Initiative in connection with National Latino Awareness Day 2007. This Initiative is being conducted in partnership with the Latino Commission on AIDS with support f
Hidden STD Epidemic Among California Youth: Treatment Costs for New Cases Each Year Exceed $1 Billion: Business Wire - October 9, 2007; OAKLAND, Calif. -- Sexually transmitted diseases (STDs), largely unreported, are costing California more than a billion dollars a year, according to a study published in the California Journal of Health Promotion. Researchers at the Public Health Institute s (PHI) Center for Research on Adolescent Health and Developmen
Inovio Biomedical Redirects Strategic Emphasis toward DNA Vaccines and DNA Delivery: Company expanding R&D to advance its DNA delivery technology and develop proprietary DNA vaccines for cancer and chronic infectious diseases: Business Wire - October 9, 2007; Inovio anticipates human data from first-in-man studies using its electroporation-mediated DNA delivery technology, adding to interim data that provided initial validation of the technology s ability to deliver and enhance potency of DNA-based immunotherapies Inovio has ample cash as it contracts the SECTA program and
Geron Corporation to Present at Biotechnology Industry Organization Investor Forum: Business Wire - October 9, 2007; MENLO PARK, Calif. -- Geron Corporation (Nasdaq:GERN) today announced that Alan B. Colowick, Ph.D., M.P.H., president, oncology, will present an update of the company s oncology programs at 10:45 a.m. PDT on Wednesday, Oct. 10, 2007, at the Biotechnology Industry Organization Investor Forum in San Francisco. The update
Novel Antiviral HIV Drug SpirH(TM) Offers New Hope for AIDS Patients Worldwide: Commences Phase II Study and Opens Enrollment for Participation of Clinics Around the World: Business Wire - October 9, 2007; LOS ANGELES -- Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer, and addiction, announced today the commencement of a 30 patient Phase II clinical trial for its new HIV-1 anti-vira
Interim Results from a New Trial of CANCIDAS(R) (caspofungin acetate) in Pediatric Patients with Documented Fungal Infections: Business Wire - October 5, 2007; SAN DIEGO -- CANCIDAS(R) (caspofungin acetate), given once daily, was evaluated as a treatment for patients three months to 17 years of age with documented or suspected fungal infections. The use of CANCIDAS in pediatric patients is investigational. Interim results from the first Phase II clinical trial to study this t
Roche and Trimeris Provide Update on Development of Alternative Administration Options for Delivery of FUZEON(R): Companies withdraw application to market Biojector(R) 2000 device for use with FUZEON: Business Wire - October 3, 2007; NUTLEY, N.J. & MORRISVILLE, N.C. -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today provided an update on our efforts to offer a needle-free device which has been investigated for use with FUZEON(R) ( enfuvirtide ). Based on comprehensive assessment of the clinical program, as well a significant delay in achieving U.
Bioject Announces Roche and Trimeris Update on the Use of Fuzeon(R) with Biojector(R) 2000: Business Wire - October 3, 2007; PORTLAND, Ore. -- Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems today announced that it has been notified by Roche and Trimeris that they will not be proceeding with their FDA submission for Fuzeon(R) to be administered with the Biojector(R) 2000 ( B2000 ).
Novel Approaches to the Study, Surveillance and Control of Infectious Diseases: Business Wire - October 3, 2007; DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c70369) has announced the addition of Encyclopaedia of Infectious Diseases: Modern Methodologies to their offering This book was developed out of the understanding that advances in infectious disease research are dependent upon the devel
GenVec Receives Second-Year Funding from NIAID for HIV Vaccine Contract: Work to Include Novel Vaccine Development and Production Scale-up: Business Wire - October 2, 2007; GAITHERSBURG, Md. -- GenVec, Inc. (Nasdaq: GNVC) announced today that the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), has executed its first option period (year two) under a previously announced five-year, $52 million contract with GenVec for the produc
Risk Managers at FERMA Help ACE Raise $40,000 for Red Cross Project: Business Wire - October 2, 2007; GENEVA, Switzerland -- European Risk Managers attending the FERMA (Federation of European Risk Managers) Congress in Geneva have helped ACE European Group (ACE)(NYSE:ACE) to raise over $40,000 (30,000 euros) for a Red Cross HIV/ AIDS educational programme in India . ACE Foundation- International con
Reality of Child Marriages Revealed in PBS Newsmagazine: NOW Hour-Long "Child Brides" Special Airs 8:30 p.m. October 12 (Check local listings): Business Wire - October 1, 2007; NEW YORK -- On October 12, the PBS weekly newsmagazine, NOW, travels around the world for a revealing exploration of forced child marriage in developing countries, and how people can act locally and globally to solve the problem. An estimated 100 million girls will be married over the next 10 years, and the hour-long s
Ichor Medical Systems' TriGrid Selected as Delivery Platform in Collaboration to Test Preventative HIV Vaccine: Partnership with Aaron Diamond AIDS Research Center and International AIDS Vaccine Initiative: Business Wire - October 1, 2007; SAN DIEGO -- Ichor Medical Systems, whose advanced electroporation system is being tested worldwide for its ability to increase the effectiveness of DNA drugs and vaccines, has entered into an agreement with two distinguished research organizations to test a promising HIV vaccine, ADVAX, in human volunteers. Under the
Argos Therapeutics' Scientific Founder Ralph Steinman, M.D., Receives Lasker Award for Basic Medical Research: Award based on discovery of dendritic cells: Business Wire - September 28, 2007; DURHAM, N.C. -- Argos Therapeutics today announced that Ralph Steinman, M.D., a scientific founder of the Company, has received the 2007 Albert Lasker Award for Basic Medical Research for his discovery of dendritic cells. Dendritic cells are a key element of the immune system, responsible for initiating and stimulating
UCLA and Orthopaedic Hospital Unveil Innovative New Research Complex: Structure's Design Encourages Collaborative Approach to Research on Stem Cells, Musculoskeletal Diseases and AIDS: Business Wire - September 27, 2007; (Editors: B-roll footage is available at http://streaming.uclahealth.org/researchbuilding2. Please note that you will need Windows Media to open the video.) LOS ANGELES -- The UCLA Biomedical Sciences Research Building and Orthopaedic Hospital Research Center, an exciting new research hub located on the UCLA campus, wa
Intel Joins Bill Clinton's Global Initiative: Former President Announces Intel's Commitment to Help Millions of Teachers Bring Technology Into Classroom - Intel Chairman Craig Barrett Named to CGI Education Advisory Committee: Business Wire - September 27, 2007; SANTA CLARA, Calif. -- Former President Bill Clinton announced today at the Clinton Global Initiative (CGI) in New York that Intel Corporation will bring its landmark teacher training program online to help more than 1.5 million teachers in 15 countries learn how to best integrate technology into their lesson plans to
Cytheris Expands Interleukin-7 Clinical Development Program With International Phase I/IIa Trial In HIV: Company Provides Update at Stockholm Symposium Sponsored by Nobel Forum Following Earlier Initiation of Trials In Hepatitis C And Oncology: Business Wire - September 26, 2007; PARIS -- Cytheris, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced expansion of the clinical trial program for CYT107, the company s recombinant human Interleukin-7 (IL-7), with the initiation of a Phase I/IIa clinical trial in HIV p
Remarks by the First Lady at a Global Health and Literacy Luncheon: Business Wire - September 24, 2007; NEW YORK -- The Pierpont Morgan Library and Museum 12:17 P.M. EDT MRS. BUSH: Thank you very much, Dr. Rice. Thank you all. Thanks so much. Thank you, Dr. Rice, for that very kind introduction. And I want to say a special welcome to Mrs. Ban. Thank you so much for welcoming all of us here for the United Nations General
Pfizer's Celsentri(R) Approved in the European Union, Providing a Novel Treatment Option for Treatment-Experienced HIV Patients: First in a New Oral Class of HIV Medicines in 10 Years: Business Wire - September 24, 2007; NEW YORK -- Pfizer Inc announced today that the European Commission (EC) has approved Celsentri(R) (maraviroc). Treatment-experienced HIV patients in the EU can soon benefit from the first CCR5 antagonist and only oral entry inhibitor. Maraviroc, in combination with other antiretroviral medicinal products, is indicated
Contributions by (RED) to the Global Fund Top $45 Million: $30 million of (RED) funds already invested in AIDS programs in Ghana, Swaziland and Rwanda: Business Wire - September 24, 2007; LOS ANGELES -- Today, (RED), the initiative launched last year to engage corporate and consumer power in the fight against AIDS in Africa, announced that the sales of (PRODUCT) RED-branded products had generated more than $45 million for the Global Fund (www.theglobalfund.org). In 2006, (RED) set out to create a sustai
Pharmaceutical Firm, ARTEC, Inc., Announces Testing Launch of TUBERCINTM -- Mission Focus is on the Testing of HIV/AIDS & Tuberculosis Patients in South Africa: Business Wire - September 24, 2007; OKLAHOMA CITY -- ARTEC, Inc., (Pink Sheets: ATKJ), visionary pharmaceutical firm, has acquired the preliminary outline to be used for the testing protocol from a sponsoring scientific group in South Africa for TUBERCINTM, a revolutionary polysaccharide compound to be used as an HIV/AIDS and ANTI-CANCER immunostimulant.
Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine Candidate: Interim Analysis of STEP Study Shows Vaccine was not Effective: Business Wire - September 21, 2007; WHITEHOUSE STATION, N.J. & SEATTLE -- Vaccination in a phase II clinical trial of Merck & Co. , Inc. s investigational HIV vaccine (V520) is being discontinued because the vaccine was not effective. The announcement was made today by the co-sponsors of this clinical trial, Merck & Co., Inc., and the HIV Vac
2007 Report Discusses the Major Peripheral Neuropathies as Well as Neuropathic Pain, Together with Prevalence, Trends and Treatment: Business Wire - September 20, 2007; DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c69049) has announced the addition of Peripheral Neuropathy and Neuropathic Pain, 2007 to their offering. Current, pipeline and emerging drugs for the treatment of peripheral neuropathy
Panacos to Present at UBS Global Life Sciences Conference: Business Wire - September 20, 2007; WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, will present at the UBS Global Life Sciences Conference to be held from September 24-27, 2007 at The Grand Hyatt in New York, NY. Dr. Alan W. Dunton, Pa
Rite Aid Pharmacies to Offer Flu Vaccinations October 16-18 at Nearly 1,700 Locations: Business Wire - September 19, 2007; CAMP HILL, Pa. -- Nearly 1,700 Rite Aid (NYSE:RAD) pharmacies will offer a one-day flu clinic on October 16, 17 or 18 to help patients stay healthy this season. Patients can receive a flu shot as well as a coupon book for items throughout the store valued at more than $230. Flu shots are free of charge for patients wit
Calypte's Aware(R) HIV-1/2 OMT Oral Fluid Rapid Test Approved in USAID Waiver List: Approval Opens $15 Billion PEPFAR Markets; Company To Hold Conference Call at 10:30 am Eastern time today: Business Wire - September 18, 2007; PORTLAND, Ore. -- Calypte Biomedical Corporation (OTCBB: CBMC), a manufacturer of medical diagnostic tests for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today that its Aware(R) HIV-1/2 OMT oral fluid rapid test has been approved by the U.S. Agency for International Developme
Data Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Demonstrate That INCB9471 is a Potent, Selective Inhibitor of the HIV-1 Virus with Excellent Pharmacokinetics Suitable for Once-Daily Dosing: Business Wire - September 18, 2007; WILMINGTON, Del. -- Incyte Corporation (Nasdaq:INCY) announced today that four scientific posters have been presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) that is being held in Chicago, Illinois. INCB9471 is a novel, orally available CCR5 antagonist that is a membe
Presidio Pharmaceuticals Adds Industry Veteran Dr. Richard Colonno as Chief Scientific Officer: Business Wire - September 18, 2007; SAN FRANCISCO -- Presidio Pharmaceuticals, Inc. announces today that internationally recognized virologist and antiviral drug discoverer Dr. Richard Colonno has joined the company as Chief Scientific Officer. Rich brings to Presidio over 25 years of experience in antiviral drug discovery and development. During his car
ISENTRESS(TM) (raltegravir), in Combination with Optimized Background Therapy (OBT), Provided Sustained Viral Suppression in Highly Treatment-Experienced Patients Infected with HIV, through 48 Weeks: Business Wire - September 18, 2007; CHICAGO -- Results from an on-going Phase II study showed that antiretroviral suppression was sustained after 48-weeks of treatment with ISENTRESS(TM) (raltegravir), an investigational oral integrase inhibitor, in combination with optimized background therapy (OBT) versus placebo plus OBT in treatment-experienced HIV-i
Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New HIV Drug Selzentry(TM) (Maraviroc): Selzentry Now Available Throughout the U.S. for Use in Combination Therapy for Certain Treatment-Experienced HIV Patients: Business Wire - September 18, 2007; NEW YORK -- Nearly three times as many patients receiving Selzentry, in addition to an optimized background regimen, achieved undetectable levels of HIV virus compared with those receiving an optimized regimen alone, according to 48 week data presented today in late-breaking sessions at the Interscience Conference on A
Pfizer to Share New Data and Portfolio Update on Infectious Disease Portfolio at ICAAC Meeting; Invites Public to View and Listen to Webcast of September 18 Analyst Meeting: Business Wire - September 13, 2007; NEW YORK -- Pfizer Inc said today that the company plans to present key data on in-line medicines and pipeline research at the Annual Meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, Illinois. In addition, Pfizer plans to host an investor meeting on September 18th to revie
OC Safari of Hope Event Returns Dignity to Kenyan Orphans: Business Wire - September 13, 2007; SANTA ANA, Calif. -- A star-lit Maasai village marketplace will greet dignitaries and guests of the first annual Safari of Hope (www.safariofhope.org) charity gala. The event, benefiting the African Child Foundation in Kenya , will take place September 22 at the Santa Ana Zoo at Prentice Park in Santa Ana, California.
World's Top Drug Researchers Unite to Accelerate Cures For TB, Malaria And HIV-AIDS: International Drug Discovery Institute (iDDi) Pioneers New Network of Experts to Address Priority Diseases: Business Wire - September 13, 2007; CHICAGO -- A group of leading drug researchers today announced the formation of a non-profit international institute to channel top talent and drug candidates from the world s leading research labs into a major, new global assault on tuberculosis (TB), malaria, and HIV/AIDS. Founders of the International Drug Discovery
Biotech 2007 to Feature Margaret G. McGlynn, R.Ph., President, Merck Vaccines and Infectious Disease: Head of global vaccine and infectious disease business will give dinner keynote address on Monday, October 8th - Biotech 2007: Business Wire - September 13, 2007; TRENTON, N.J. & MALVERN, Pa. -- The Biotechnology Council of New Jersey (BCNJ) and Pennsylvania Bio announce that Biotech 2007: Imagine. Collaborate. Innovate (www.biotech2007.org), to be held on October 8-9, 2007, at the Loews Philadelphia Hotel, will feature as a keynote speaker Margaret G. McGlynn, R. Ph., presi
Zacks.com Announces That Nadine Wong Highlights: Gilead: Business Wire - September 12, 2007; CHICAGO -- Nadine Wong, editor of the BioTech Stock Report newsletter, says Gilead (Nasdaq: GILD) is well positioned to remain a leader in new antivirals. Check out her recent comments and learn more about this biotech. Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84 Highlights from t
AntiCancer, Inc. Receives Patent for New Type of AIDS Drug: Business Wire - September 12, 2007; SAN DIEGO -- AntiCancer, Inc. announced today that it has received patent 7,264,819 on September 4, 2007, entitled Lyase treatment for P. carinii . AntiCancer is currently developing a recombinant bacterial protein drug called PEG-methioninase (methionine lyase) for cancer treatment. This drug is now in late preclinica
University of Miami School of Nursing and Health Studies Receives Major Federal Grant to Address Hispanic Health Issues: Business Wire - September 12, 2007; CORAL GABLES, Fla. -- The University of Miami School of Nursing and Health Studies has received a $7 million, five year grant from the National Institutes of Health (NIH). These funds will create El Centro, a National Center on Minority Health and Health Disparities (NCMHD) University of Miami Center of Excellence for
Inhibitex Licenses HIV Integrase Inhibitor Program: Business Wire - September 11, 2007; ATLANTA -- Inhibitex, Inc. (Nasdaq: INHX) announced today that it has entered into an exclusive worldwide license agreement with the University of Georgia Research Foundation (UGARF) for intellectual property covering a series of HIV integrase inhibitors and other antiviral compounds in exchange for an upfront license
FDA Advisory Committee Unanimously Recommends Accelerated Approval of ISENTRESS(TM) (raltegravir), Merck's Investigational Oral Integrase Inhibitor, for Treatment of HIV: Business Wire - September 5, 2007; WHITEHOUSE STATION, N.J. -- Merck & Co. , Inc. announced today that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration ( FDA ) voted unanimously to recommend accelerated FDA approval of ISENTRESS(TM) (raltegravir) in combination with other antiretroviral therapy (ART) for the treatment
Advanced Viral Research Corp. to Initiate Phase II Trial in Cancer Patients: Business Wire - September 5, 2007; YONKERS, N.Y. -- Advanced Viral Research Corp. (OTCBB:ADVR), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, announced today plans to initiate a Phase II clinical trial to evaluate the effectiveness of its compound AVR118 in the treatment of cachexia-related symptoms
Patent Application Licensed to CytRx Subsidiary RXi Pharmaceuticals Issues in Australia With Broad Claims to Expressed RNAi: Business Wire - September 5, 2007; LOS ANGELES -- CytRx Corporation s (NASDAQ:CYTR) majority-owned subsidiary, RXi Pharmaceuticals Corporation (RXi), today announced the grant of an Australian patent issued to the University of Massachusetts Medical School covering in vivo production of small interfering RNA (siRNA) that mediate gene silencing. The gran
Calypte Opens Dubai Office: New Location to Drive Growth Throughout Middle East and Northern Africa: Business Wire - September 5, 2007; LAKE OSWEGO, Ore. -- Calypte Biomedical Corporation (OTCBB: CBMC), medical diagnostic tests manufacturer for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today that it has established a branch office in Dubai, United Arab Emirates (UAE) as the Company s regio
Aethlon Medical Initiates Hemopurifier(R) Shipments to India: Business Wire - September 5, 2007; SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) disclosed today that it has shipped Hemopurifier(R) treatment cartridges to support a clinical study to be conducted at the Fortis Hospital (www.fortishealthcare.com) in Delhi, India . The study, which will evaluate the safety of the Hemopurifier(R) in ten patients, is e
Herbalife Family Foundation Opens Program in Zambia: Business Wire - September 4, 2007; LOS ANGELES -- The Sara Rose Children Foundation, Inc. received a grant from Herbalife Family Foundation s Casa Herbalife program to improve its ability to serve healthier food to children living in its new facility in Kitwe, Zambia . In response to the growing number of orphans and abandoned children affected by the A
Tibotec Pharmaceuticals Ltd Returns MIV-210 Licensing Rights to Medivir: Business Wire - September 4, 2007; STOCKHOLM, Sweden -- Regulatory News: Medivir (STO:MVIRB) has today announced that the licensing rights for MIV-210 have reverted to Medivir from Tibotec Pharmaceuticals Ltd. In previously performed pre-clinical trials, MIV-210 has demonstrated very potent activity against Hepatitis B Virus (HBV) and has good pharmacok
Medivir: New Partner for MIV-210: Business Wire - September 4, 2007; STOCKHOLM, Sweden -- Regulatory News: Medivir AB (STO:MVIRB) has today entered a licensing agreement with the Chinese pharmaceutical company Hainan Noken Pharmaceutical Industry Ltd in relation to the antiviral compound MIV-210. MIV-210 is a polymerase inhibitor and belongs to the group of projects which is administere
Over 80% of Patients on ATC Achieve Undetectable HIV After 24 Weeks: Business Wire - September 4, 2007; MELBOURNE, Australia -- Melbourne-based biotechnology company Avexa Limited (ASX:AVX) announced today positive 24 week data from the phase 2b clinical trial of apricitabine (ATC). The data demonstrate that, in over 80% of patients treated with ATC, the level of HIV in the blood was reduced to below detectable levels af
Panacos to Present at Bear Stearns Healthcare Conference: Business Wire - August 31, 2007; WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, will present at the 20th Annual Bear Stearns Healthcare Conference to be held from September 10-11 at The Grand Hyatt in New York, NY. Dr. Alan W. Dunto
Medivir to Receive Shares in Presidio Pharmaceuticals: Business Wire - August 30, 2007; STOCKHOLM, Sweden -- Regulatory News: A completed share issue of USD 26m in the San Francisco-based company Presidio Pharmaceuticals, Inc., Medivir s (STO:MVIRB) licensing partner for the antiviral compounds alovudine (MIV-310) and PPI-801/802 (MIV-410), will trigger Medivir receiving Series B shares in Presidio. S
New Book Tells Story of Princess Diana's Posthumous Impact and the Incredible Journey of Her Royal Dresses: "I hope the people who buy my dresses use them to bring succor and support to those in need." -Diana, Princess of Wales, As quoted by Vogue Magazine, May 1997, just prior to the June 1997 Christie's sale of Diana's dresses.: Business Wire - August 29, 2007; TAMPA, Fla. -- The People s Princess Charitable Foundation, Inc. announced today the release of My Decade with Diana - the Perpetual Power of the People s Princess, a heavily illustrated coffee table book, which reveals the story of Princess Diana s heartfelt wish to help the less fortunate by using beautiful things to
Presidio Pharmaceuticals Closes $26 Million Series B Financing: Business Wire - August 29, 2007; SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing novel, small molecule compounds for the treatment of HIV-1, HCV and other chronic viral infections, announced today that it has closed a $26 million Series B financing led by Panor
Republic of Kenya Adopting New HIV Self Testing Program: Policy Promotes Oral Fluid Testing: Business Wire - August 28, 2007; LAKE OSWEGO, Ore. -- Calypte Biomedical Corporation (OTCBB: CBMC), a manufacturer of medical diagnostic tests for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today its support for the guidance policy unveiled last week by the National AIDS Control Council (NACC) of
Allion Healthcare, Inc. to Present at the Thomas Weisel Partners Healthcare Conference 2007: Thomas Weisel 2007 Healthcare Conference: Business Wire - August 23, 2007; MELVILLE, N.Y.--Allion Healthcare, Inc. (NASDAQ: ALLI), a national provider of specialty pharmacy and disease management services focused on HIV/AIDS patients, announced today it will participate in the Thomas Weisel Partners Healthcare Conference 2007 in Boston, Massachusetts at Four Seasons Boston, September 5th thro
Examine Detailed Information on the Current Drug Pipeline for AIDS and HIV: Business Wire - August 23, 2007; DUBLIN, Ireland--Research and Markets (http://www.researchandmarkets.com/reports/c66470) has announced the addition of Infections - AIDS HIV Drug Pipeline Report to their offering. Infections - AIDS HIV Drug Pipeline Report contains detailed information on the current drug pipeline. This report provides insight into th
Encouraging Phase II Data on HIV Vaccine Utilizing GenVec Technologies Presented at Seattle AIDS Conference: Business Wire - August 23, 2007; GAITHERSBURG, Md.--GenVec, Inc. (Nasdaq:GNVC) announced that results from multiple ongoing clinical trials utilizing its adenovector vaccine technologies were presented yesterday at the AIDS Vaccine 2007 Conference taking place in Seattle, Washington this week. The trials, which are investigating a DNA prime- adenovira
Etubics Awarded Grant from the National Institute of Health for Continued Development of HIV Vaccine: Business Wire - August 23, 2007; SEATTLE--Etubics Corporation, a Seattle-based biopharmaceutical company, has announced that it has received a Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) in the amount of $600,000. The grant will be use
Two Separate Studies Presented at the AIDS Vaccine 2007 Conference Show Improved Results with the Biojector(R)2000: Studies Report Significantly Improved Results with Needle-Free Delivery - AIDS Vaccine 2007 Conference: Business Wire - August 22, 2007; PORTLAND, Ore.--Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems, today reported results from two studies presented at the AIDS Vaccine 2007 Conference in Seattle, Washington, which showed significantly improved results when the Biojector(R)2000 ( B2000 ) needle-
Organizations Partner to Build Center for Women and Children in Africa: Business Wire - August 21, 2007; CHARLESTON, S.C.--Gethsemani Circle of Friends, a North Charleston nonprofit organization and the Family Services Research Center at the Medical University of South Carolina (MUSC) are partnering with Nkabom Artist and Craftspeople Association of Accra, Ghana to build a center in Okurase, Ghana that will provide arts-b
Etubics Reports Breakthrough Next Generation HIV Vaccine at AIDS Conference: AIDS Vaccine 2007 Conference: Business Wire - August 21, 2007; SEATTLE--At the AIDS Vaccine 2007 Conference today, Etubics Corporation reported on a novel adenovirus vector vaccine that can boost the HIV/AIDS virus immune response and deliver vaccination against a second disease at the same time. For the first time ever, Etubics has demonstrated that animals can be immunized again
Medivir Transfers the Licensing Rights of MIV-160: Business Wire - August 21, 2007; STOCKHOLM, Sweden--Regulatory News: Medivir AB (STO:MVIRB) has succeeded in transferring the licensing agreement on the anti-HIV compound MIV-160 from Guangdong Lantai-Viewland Pharmaceutical Co. Ltd. to Beijing Mefuvir Medicinal Technology Co. Ltd, a subsidiary of one of China s largest condom manufacturers. The compa
Amazon.com and Arista Records Premiere Exclusive, Worldwide Release of New Annie Lennox Music Video on Amazon.com: "Dark Road" Video is Only Available for Viewing on Online Retailer's Web Site: Business Wire - August 17, 2007; SEATTLE & NEW YORK--Amazon.com (NASDAQ:AMZN) and Arista Records, will release on Monday the exclusive, worldwide premiere of the new Annie Lennox video Dark Road on www.amazon.com. For 48 hours, fans around the world will get their first and only look at the new video online at Amazon.com. Dark Road is the first tr
Pharmaceutical Firm, ARTEC, Inc., Announces Key Appointments � Leading Product Advancement & Global Integration: Business Wire - August 16, 2007; OKLAHOMA CITY--Dr. Ronald Shinn, President and Board of Directors Chairman of ARTEC, Inc. (Pink Sheets:ATKJ), a company in the process of enterprising a revolutionary polysaccharide compound to be used as an HIV/AIDS and ANTI-CANCER immunostimulant, trade named TUBERCINTM, announces key appointments today. The company
SRI International Awarded National Institute of Allergy and Infectious Disease Contract to Develop AIDS Drug Formulations: Business Wire - August 16, 2007; MENLO PARK, Calif.--SRI International, an independent nonprofit research and development organization, today announced that it has been awarded a $4.6 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to research, develop and manufacture
Inovio Biomedical Partner Tripep Receives Approval to Initiate Phase I/II Study of Novel Vaccine for Hepatitis C Virus: Business Wire - August 16, 2007; SAN DIEGO--Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB of Sweden , received approvals from the Swedish Medical Products Agency and local ethics committees to initiate a Phase I/II cli
BearingPoint Awarded AIDS Support And Technical Assistance Resources Contract: $200 Million Ceiling for USAID's "AIDSTAR" Contract: Business Wire - August 13, 2007; MCLEAN, Va.--BearingPoint, Inc. (NYSE:BE), one of the world s largest management and technology consulting firms, announced that the United States Agency for International Development (USAID) has named BearingPoint as one of six awardees of the AIDS Support and Technical Assistance Resources Contract (AIDSTAR). The con
Premier Educates Continuum of Care Market on Preventing Needlestick and Sharps Injuries: Safety Institute Brochure Mailed to Members and Available Online: Business Wire - August 09, 2007; CHARLOTTE, N.C. -- As part of its commitment to improve worker and patient safety, the Premier Safety Institute this week mailed its new Prevent Needlestick Injuries brochure to Premier members across the continuum of healthcare delivery sites, including surgery centers, home healthcare facilities, imaging centers, cli
This Volume Draws Together Significant Articles Addressing the Challenges of Applying Human Rights to Promote Health: Business Wire - August 9, 2007; DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c65222) has announced the addition of Health and Human Rights to their offering. This volume draws together significant articles addressing challenges of applying human rights to promote health in settings ranging from the local to the g
Sub-Saharan African Countries Escalate Efforts to Regulate Medical Devices and Pharmaceutical Products Through Strict Legislation: Business Wire - August 09, 2007; DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c65154) has announced the addition of the new Frost & Sullivan Report The Regulatory Environment for Pharmaceutical Products and Medical Devices in Key Sub-Saharan African Countries to their offering. This Frost & Sullivan r
Avexa Positioned to Launch Phase III Clinical Trial of ATC: Business Wire - August 09, 2007; MELBOURNE, Australia -- Avexa Limited (ASX:AVX) announced today its full year financial result for 2007. The Company reported a closing cash balance of $76.9 million and negative operating cash flows for the year of approximately $15.6 million. CEO Dr Julian Chick said, The 2007 financial year saw the Company achieve i
Nutra Pharma Announces Positive Results of ReceptoPharm Pain Study: Business Wire - August 08, 2007; BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS) has today announced that its drug development holding, ReceptoPharm, has successfully completed a study of RPI-78. RPI-78 is ReceptoPharm s lead drug candidate being studied for the
Entry of New Drug Classes Redefining the HIV Market: Business Wire - August 8, 2007; DUBLIN, Ireland -- Research and Markets http://www.researchandmarkets.com/reports/c65109 has announced the addition of The Global HIV/AIDS Market Outlook to 2012 to their offering. Some key findings from this report... - The HIV market is forecast to expand at a CAGR of 10.3% over the period 2006-12.
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009 - Company Focused on Areas of High Medical Need Including Cancer, Heart Disease, Pain, Neurological Disorders and Infectious Diseases - Update Posted Online Today Shows 99 Programs Across 11 Therapeutic Areas, With 47 in Phase II and Significant Growth in Biologics: Business Wire - August 06, 2007; NEW YORK -- Pfizer said today that it now has a total of 47 programs in its Phase II Research and Development pipeline, which is the largest Phase II cohort in its history and represents continued progress toward its target of tripling the company s Phase III portfolio by 2009. The growth of our Phase II cohort is
Humanitarian Groups Forge Medical Supply Pipeline for AIDS Patients in South Africa: Business Wire - August 6, 2007; ALEXANDRIA, Va. -- The Foundation for Hospices in Sub-Saharan Africa, in collaboration with Direct Relief International, is launching a supply chain program to get hospice and palliative care supplies to HIV/AIDS patients in the Eastern Cape of South Africa . This program will bring necessary provisions such as antibio
Pfizer's Selzentry(TM) (Maraviroc) Tablets, Novel Treatment for HIV, Approved by FDA: First in a New Class of Oral HIV Medicines in More Than a Decade: Business Wire - August 6, 2007; NEW YORK -- Pfizer Inc announced today that the U.S. Food and Drug Administration ( FDA ) has approved Selzentry(TM) (maraviroc) tablets, the first in a new class of oral HIV medicines in more than 10 years. Selzentry blocks viral entry into white blood cells, significantly reducing viral load and increasing T-cell cou
Focus on the HIV / AIDS Market - Epidemiological Analysis, Leading Brands of Treatment, Market Trends and Key Pharmaceutical Companies: Business Wire - August 02, 2007; LYON, France -- Reportlinker.com announces that a new market research report related to the worldwide infectious diseases industry is now available to its catalogue. The Global HIV/AIDS Market Outlook to 2012 http://www.reportlinker.com/p056755/HIV-AIDS-Market.html Some key findings from this report... -- The HIV m
NovaDel Announces Sublicense Agreement for Zensana(TM): Partnership with Par Pharmaceuticals Provides Best Strategic Path for Promising Drug: Business Wire - August 01, 2007; FLEMINGTON, N.J. -- NovaDel Pharma Inc. (AMEX: NVD), today announced that Par Pharmaceuticals has been granted sublicense rights for the development and commercialization of Zensana(TM) (ondansetron HCl, oral spray). Ondansetron is a 5-HT3 antagonist to prevent nausea and vomiting after chemotherapy, radiation and surg
Panacos Reports Second Quarter 2007 Financial Results: Business Wire - July 31, 2007; WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced its financial results for the quarter ended June 30, 2007 and reviewed progress in its development programs. Recent Business Highlights:
Orphans with HIV/AIDS and Family Health and Wellness Programs to Benefit from Constella's Enhancing Human Health Grants: Business Wire - July 30, 2007; DURHAM, N.C. -- Constella Group, a leading global provider of professional health services, announced that it has awarded $20,000 to four organizations to improve the lives of orphans living with HIV/AIDS, to reduce stigma and discrimination associated with HIV and sexually transmitted diseases, to promote health and w
Incyte Cites Encouraging Clinical Data in Multiple Programs; Announces Second Quarter 2007 Financial Results: Conference Call and Webcast Scheduled for 8:30 a.m. ET Today: Business Wire - July 26, 2007; WILMINGTON, Del. -- Incyte Corporation (Nasdaq:INCY) today provided a review of the Company s recent progress for its lead drug discovery and development programs in HIV, oncology, diabetes and inflammation and reported second quarter 2007 financial results. Paul A. Friedman, Incyte s President and Chief Executive Offi
OraSure Technologies Signs Agreement with the Supply Chain Management System for Supply of OraQuick(R) HIV Test to PEPFAR Countries: Business Wire - July 26, 2007; BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced the execution of an agreement for the supply of its OraQuick(R) Rapid HIV-1/2 Antibody Test to the Supply Chain Management System ( SCMS ). Created with funds from the President s Emergency Plan for
Avexa Releases ATC Phase IIb Clinical Trial Update: Business Wire - July 26, 2007; MELBOURNE, Australia -- Australian biotechnology company Avexa (ASX:AVX) announced today further information relating to its Phase IIb clinical trial on apricitabine (ATC) as presented by Dr Pedro Cahn to the International AIDS Society (IAS) meeting in Sydney yesterday afternoon. Dr Cahn is not only one of Avexa s lead
Remarks by the First Lady to National Press Club Newsmakers Luncheon - National Press Club: Business Wire - July 25, 2007; WASHINGTON -- MRS. BUSH: Thank you all. Thank you, Jerry. Thanks everybody. The promise that I would never have to give a political speech was actually our pre-nup. (Laughter.) But it did -- I also promised that I would run with George, be a jogger with him -- and I never once did it, so I guess I don t feel that bad a
Progenics Presents Additional Positive Clinical Results for HIV-Entry Inhibitor PRO 140 at International AIDS Meeting: Significant and prolonged viral load reduction in HIV-infected individuals after treatment with single-dose of CCR5 monoclonal antibody PRO 140 - Subcutaneous form of PRO 140 developed for phase 2 clinical testing, 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention: Business Wire - July 25, 2007; SYDNEY, Australia -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today presented new findings from a phase 1b clinical trial of PRO 140 in individuals infected with the human immunodeficiency virus (HIV), the causative agent of AIDS. At the 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatme
Panacos Announces Five Presentations on its Antiviral Programs at International AIDS Society Conference: Business Wire - July 25, 2007; WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that its programs were the subject of five poster presentations at the fourth International AIDS Society Conference on Pathogenesis, Tr
ISENTRESS(TM) (raltegravir), an Investigational Oral HIV Integrase Inhibitor, in Combination Therapy Demonstrated HIV RNA Reduction Comparable to Efavirenz in Treatment-Naive HIV-Positive Patients: Data Showed Effects Sustained to 48 Weeks with Minimal Effect on Lipid Levels in Previously Untreated Patients: Business Wire - July 24, 2007; SYDNEY, Australia -- Results from an ongoing 48 week Phase II study of ISENTRESS(TM) (raltegravir), an investigational oral HIV integrase inhibitor, under development by Merck & Co. , Inc., in combination with tenofovir (
Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48 Week Data Show: Business Wire - July 24, 2007; NEW YORK -- Rates of virologic suppression in patients receiving Pfizer s novel CCR5 antagonist, maraviroc, compared to efavirenz (EFV) were 70.6% vs. 73.1% for less than400 copies/ml and 65.3% vs. 69.3% at less than50 copies/ml in the full analysis set (FAS) study population (n= 360, maraviroc/ n= 361, efavirenz), acc
Inovio Biomedical Establishes Agreements with National Cancer Institute and International Aids Vaccine Initiative to Conduct Research Using Inovio's DNA Delivery Technology: Business Wire - July 24, 2007; SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today its wholly-owned subsidiary, Genetronics, Inc., has entered into separate collaboration agreements with two
Phase IIa Study Results Demonstrate that Once-Daily 200 mg Dosing of INCB9471 Provided Potent and Prolonged Antiviral Activity in HIV-Infected Patients: Results Suggest that INCB9471 Has the Potential to Provide Advantages over Other CCR5 Antagonists in Development: Business Wire - July 24, 2007; SYDNEY, Australia -- Results from a 14-day Phase IIa clinical trial, presented today at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, demonstrate that INCB9471, an investigational drug for the treatment of HIV-1, the retrovirus that causes the acquired immunodeficiency syn
144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney: Business Wire - July 23, 2007; SYDNEY, Australia -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced the presentation of 144-week data from an ongoing clinical trial, Study 934, comparing a once-daily regimen of Truvada (R) (emtricitabine and
HIV Report Gives Detailed Analysis of the Antiretroviral Therapy Market: Business Wire - July 23, 2007; DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c63496) has announced the addition of Commercial Insight: HIV - Reshaping Treatment Paradigms to their offering. Detailed analysis of the antiretroviral therapy market. 10 year sales forecast for marketed drugs and key pipeline compounds
Pfizer Receives Positive Opinion from CHMP for Celsentri(R) (maraviroc) for Treatment-Experienced Patients Infected with CCR5-Tropic HIV-1: Business Wire - July 20, 2007; NEW YORK -- Pfizer Inc announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending marketing authorization for Celsentri(R) (maraviroc), the first CCR5 antagonist for use in combination with other antiretroviral agents for
OraSure Technologies Announces Pre-Clinical Study Results for Prototype Rapid HCV Antibody Test at AACC Annual Meeting: Prototype Test Performance Equivalent to Lab-Based Testing in Pre-clinical Trials of Human Subjects: Business Wire - July 19, 2007; BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced pre-clinical study results for a prototype rapid Hepatitis C ( HCV ) antibody test on the Company s OraQuick(R) test platform, using oral fluid, finger-stick whole blood, venous whole blood, serum an
Profectus BioSciences, Inc. Receives NIH Grant to Enhance Future Anti-HIV Therapies - Small Business Innovative Research (SBIR) Grant from National Institute of Allergy and Infectious Diseases: Business Wire - July 18, 2007; BALTIMORE -- Profectus BioSciences, Inc., a biotechnology company that develops preventative and therapeutic technologies to reduce the morbidity and mortality caused by viral diseases, today announced the award of an approximately $200,000 Phase 1 Small Business Innovative Research (SBIR) grant from the National Insti
Aethlon Medical Announces Cancer Treatment Discovery: Business Wire - July 18, 2007; SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) announced today that researchers have discovered the Aethlon Hemopurifier(R) is effective in capturing particles that suppress the immune response in cancer patients. The particles, known as exosomes, are released by solid tumors, lymphomas, and leukemia. Exosomes induce
Aethlon Medical to Host Webcast Today at 4:05 pm EDT: Business Wire - July 17, 2007; SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) will host a webcast this afternoon to discuss pre-clinical testing of the Aethlon Hemopurifier(R) as a potential cancer therapy. The webcast will begin at 4:05 pm EDT (1:05 pm PDT) and can be accessed online at: www.aethlonmedical.com/news/cancer.htm. About Aethlon Medica
Siemens Unveils New Solutions to Improve Laboratory Workflow at the American Association of Clinical Chemistry (AACC) Conference: Siemens Medical Solutions Diagnostics Offers Integrated Solutions for Enhanced Clinical Workflow: Business Wire - July 16, 2007; SAN DIEGO -- Siemens Medical Solutions Diagnostics (www.siemens.com/diagnostics) is showcasing its comprehensive portfolio of performance-driven solutions for the first time at the American Association of Clinical Chemistry (AACC) Conference in San Diego (July 17 - 19, booth #3411)*. This portfolio is a result of bring
BioScrip, Inc. Awarded National HIV/AIDS and Transplant Specialty Contract by UnitedHealthcare: Business Wire - July 16, 2007; ELMSFORD, N.Y. -- BioScrip, Inc. (Nasdaq: BIOS) announced today that UnitedHealthcare, a UnitedHealth Group (NYSE: UNH) company, has awarded BioScrip an agreement to serve as one of two national specialty pharmacy providers of HIV/AIDS and Solid Organ Transplant drugs and services to UnitedHealthcare and its participat
Dade Behring and Roche Grant HIV-1 Group O Rights to DiaSorin: Agreement further widens access to common HIV test: Business Wire - July 16, 2007; DEERFIELD, Ill. -- Dade Behring Inc. (NASDAQ:DADE) and Roche Diagnostics announced today that they have granted DiaSorin certain rights related to the development, marketing and manufacturing of immunoassays that can be used for the detection of HIV(human immunodeficiency virus)-1 group O. HIV tests are used to screen
Progenics Selected to Present Clinical Results for Novel HIV Therapy PRO 140 at International Aids Conference: Late-breaker oral presentation on viral-entry inhibitor to be webcast: Business Wire - July 12, 2007; TARRYTOWN, N.Y. -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced that it has been selected to present results from a phase 1b clinical trial of PRO 140, an investigational drug for the treatment of HIV/AIDS, at the 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Preve
Blue Shield of California Foundation Awards $11.3 Million to Nonprofits Statewide to Promote Access to Health Care and Health Technology: $7 Million to Fund Community Clinics; Another $1 Million Goes to Rural Health Networks: Business Wire - July 10, 2007; SAN FRANCISCO -- Blue Shield of California Foundation (BSCF) today announced grants totaling nearly $11.3 million, including up to $7 million to increase access to health care for uninsured Californians through an initiative that will provide funding to community-based clinics throughout the state. BSCF is also giving
Nutra Pharma Announces Successful Enrollment in ReceptoPharm Adrenomyeloneuropathy (AMN) Study: Business Wire - July 10, 2007; BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS) has today announced that its drug development holding, ReceptoPharm, has successfully completed enrollment in its phase IIb human clinical trial for the treatment of Adrenomyeloneur
Remarks by the President in a Conversation on the Americas: Business Wire - July 09, 2007; ARLINGTON, Va. Hyatt Regency Crystal City 10:30 A.M. EDT THE PRESIDENT: Thank you all. Please be seated. Thanks for coming today. In my recent trip down to Central and South America, I told the folks that we were going to host a conference here in Washington, a conference to promote best practices, which really says, h
Remarks by the First Lady at a White House Conference on the Americas: Business Wire - July 09, 2007; ARLINGTON, Va. Hyatt Regency Crystal City 1:55 P.M. EDT MRS. BUSH: Thank you all very much. Thanks so much. I m so happy to be with you today at this very important summit. I want to recognize Carlos Gutierrez, the Secretary of the United States -- U.S. Commerce, who is here, Department of Commerce; Dr. Tom Shannon, th
CNN Reports on Aethlon Medical: Business Wire - July 09, 2007; SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, today disclosed that its Hemopurifier(R) treatment technology is the feature of a CNN Pioneers news story. The story can be accessed at: http://www.cnn.com/video/#/video/bestoftv/2007/07/08/ pioneers.blo
Kylin Therapeutics Licenses an RNAi Delivery Technology from Purdue University: Business Wire - July 09, 2007; WEST LAFAYETTE, Ind. -- Purdue Research Foundation announced Monday (July 9) that it has granted Purdue Research Park startup company Kylin Therapeutics Inc., an exclusive license to commercialize a biotechnology that will better target RNA interference (RNAi) delivery technology to combat disease-causing genes. The li
Medivir Announces Bristol-Myers Squibb has Terminated Their Agreement for the Development of Medivir's Preclinical Polymerase Inhibitor, MIV-170: Business Wire - July 06, 2007; STOCKHOLM, Sweden -- Regulatory News: Medivir (STO:MVIRB) today announced that Bristol-Myers Squibb (NYSE:BMY) has terminated the development of the preclinical HIV compound MIV-170. The compound did not meet the profile desired by Bristol-Myers Squibb. MIV-170 belongs to the group of polymerase inhibitors that Medivir
Avexa's Apricitabine Clinical Trial Update: ATC Completes 24 Week Milestone of Phase IIb Trial: Business Wire - July 05, 2007; MELBOURNE, Australia -- Australian biotechnology company Avexa (ASX:AVX) announced today the completion of apricitabine s controlled, double blinded phase which represents the first 24 week segment of its Phase IIb trial. Patients have now progressed into the open-label section of the trial (weeks 24 to 48) and will co
Hercules Provides $20 Million to Panacos Pharmaceuticals, Inc., a Biopharmaceutical Company Developing Novel Antiviral and HIV Therapies: Business Wire - July 02, 2007; PALO ALTO, Calif. -- Hercules Technology Growth Capital, Inc. (NASDAQ:HTGC), a leading specialty finance company providing growth capital in the form of venture debt and equity to venture capital and private equity backed technology and life science companies at all stages of development, today announced that on June 2
Energex System's Experimental Non-Pharmacological Treatment Exceeds Expectations in Reducing Liver Inflammation in Refractory Hepatitis C Patients: Business Wire - June 28, 2007; EMERSON, N.J. -- Energex Systems, Inc. announced today that its experimental therapy known as HemoModulation was effective in reducing viral load and liver inflammation in non-responding Hepatitis C patients. The trial was conducted under an Investigational Device Exemption (IDE) that was granted by the Federal Food an
Aethlon Medical to Host Webcast Event on July 17th at 4:05 pm EDT: Business Wire - June 28, 2007; SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, has scheduled a special webcast event to report on pre-clinical testing of the Aethlon Hemopurifier(R) in cancer therapy. The webcast will begin at 4:05 pm EDT on Tuesday, July 17th. Aethlon CEO, James A
Remarks by the First Lady at Mututa Memorial Center: Business Wire - June 28, 2007; LUSAKA, Zambia - Mututa Memorial Center, Lusaka, Zambia, 1:17 P.M. (Local) MRS. BUSH: Thank you very much, Bruce. Thank you for your very kind introduction, for showing us all the great things that you ve shown us today. I want to recognize Mrs. Maureen Mwanamasa. Thank you very much. Thank you for your hospitality to
Statement by the First Lady at the PlayPump Launch: Business Wire - June 28, 2007; LUSAKA, Zambia Regiment Basic School 10:46 A.M. (Local) MRS. BUSH: I want to thank you for coming out today to cover this PlayPump. This is one of the commitments that the United States government made in cooperation with several foundations, as well -- the Case Foundation and the United States -- the PlayPump Foundati
Interview of the First Lady by ABC News, Good Morning America: Business Wire - June 27, 2007; MAPUTO, Mozambique Via Satellite Q -- (in progress) -- President Bush, of course, has called to double funding for AIDS relief in the next five years, to $30 million. That s a move that even impressed his critics, and it can t come too soon: Last year alone, AIDS killed 2.1 million Africans, leaving 12 million orphans.
Interview of the First Lady by CBS News, Early Show: Business Wire - June 27, 2007; MAPUTO, Mozambique Via Satellite Q First Lady Laura Bush is on her third trip to Africa, on a mission to fight AIDS and Malaria, and also raise awareness of women s issue. She arrived in Senegal Monday night, then traveled to Mozambique. Later this week she ll visit Zambia and
Interview of the First Lady by FOX News, Fox and Friends: Business Wire - June 27, 2007; International News Desks/National Desks MAPUTO, Mozambique -- Via Satellite Q With the United States strong commitment to helping countries in need, First Lady Laura Bush is leading the fight against deadly diseases in Africa. She joins us live from Mozambique, the capital city there, to discuss the differences being m
Aethlon Medical Announces Approval of Clinical Study: Business Wire - June 27, 2007; SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) announced today that it has received approval to initiate clinical testing of the Hemopurifier(R) in human studies to be conducted at the Fortis Hospital (www.fortishealthcare.com) in Delhi, India . The study, approved by the Ethics Committee for Research at Fortis Hospi
FDA Priority Review Granted for ISENTRESS(TM) (raltegravir), Merck's Investigational Integrase Inhibitor for HIV: Business Wire - June 27, 2007; Investigational Integrase Inhibitor a New Class of Oral HIV Medication WHITEHOUSE STATION, N.J. -- Merck & Co. , Inc. (NYSE: MRK) announced today that the U.S. Food and Drug Administration ( FDA ) has accepted the New Drug Application (NDA) for ISENTRESS(TM) (raltegravir, previously known as MK-0518). Data in the N
Remarks by the First Lady after Tour - Fann Hospital, Dakar, Senegal: Business Wire - June 26, 2007; DAKAR, Senegal 9:39 A.M. (Local) MRS. BUSH: I thank everyone for coming to Fann Hospital today to see what I ve gotten to see. First, I think it s often overlooked, that one essential thing in the treatment of AIDS, or HIV, is good nutrition. And the gardens that we ve seen here at the Fann Hospital give patients who a
Nigeria's Pharmaceutical Market Value is Set to Reach only US$298mn in 2010: Business Wire - June 26, 2007; DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c60814) has announced the addition of Nigeria Pharmaceuticals & Healthcare Report Q4 2006 to their offering. The Nigeria Pharmaceuticals & Healthcare Report provides independent forecasts and competitive
Nantero Announces Licensing to Alpha Szenszor, Inc.: Start up Developing Portable and Cost-effective Detectors for Infectious Diseases Including HIV: Business Wire - June 26, 2007; WOBURN, Mass. -- Nantero, Inc., a nanotechnology company using carbon nanotubes for the development of next-generation semiconductor devices, has provided license rights for biomedical sensors to Alpha Szenszor, Inc., a newly-formed company also based in Woburn, Massachusetts. Alpha Szenszor is developing a suite of se
OraSure and the National Association of People with AIDS Launch Third Annual "Mayors Campaign against HIV(TM)" for National HIV Testing Day: 33 U.S. Mayors Unite to Promote HIV Screening on June 27th, National HIV Testing Day - OraSure, NAPWA, City, State and Local Agencies to Open NASDAQ Stock Market: Business Wire - June 26, 2007; BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR) and the National Association of People with AIDS (NAPWA) announced today the launch of the third annual Mayors Campaign Against HIV(TM), a national campaign to encourage testing for HIV and promote the benefits of knowing one s HIV status. The Campaign is being
Keep the Light Alive II Run/Bike Tour to Support the Safe Haven Project Kicks off in Albany, New York: Founder Embarks on Three-Day Journey from Capital to Capital to Raise Awareness and Funding on Behalf of Young People Living with HIV and AIDS: Business Wire - June 26, 2007; NORTHAMPTON, Mass. -- The Safe Haven Project announced today the kick off of the Keep the Light Alive II Run/Bike tour. Led by founder and CEO Dave Butler, the 3-day journey to benefit The Safe Haven Project will begin in Albany, New York on Friday, June 29 and end on Sunday, July 1 in Boston Common. Along the way, But
Magic Johnson Foundation Observes National HIV Testing Day by Offering Free Testing for Tickets: Business Wire - June 26, 2007; The Magic Johnson Foundation, Inc.: WHO: The Magic Johnson Foundation, Inc. WHAT: The Magic Johnson Foundation, Inc., in partnership with AIDS Healthcare Foundation, Charles R. Drew University, Los Angeles County STD Programs Office and Minority AIDS Project will observe the 13th annual National HIV Testing Day by host
Press Briefing by the First Lady En Route Dakar, Senegal: Business Wire - June 25, 2007; DAKAR, Senegal Aboard Plane 10:21 A.M. EDT MRS. BUSH: Thanks, everyone. I just came out to say hello, and I m glad you re with me. So I think we re going to have a very interesting trip. It s going to be a difficult trip, just because it s so much travel. We re going, obviously, from the west coast to the east coast an
Second Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint: Business Wire - June 25, 2007; FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced that Study 103, a Phase III clinical trial evaluating the company s once-daily anti-HIV drug Viread (R) ( tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potentia
HIV Testing Week Kicks Off in the Los Angeles Area with Free HIV Testing for the Public Beginning June 25: Business Wire - June 22,2007; Los Angeles County Office of AIDS Programs and Policy: WHAT: Hundreds of Los Angeles County residents are expected to receive FREE, anonymous and confidential HIV testing during HIV Testing Week, held this year from June 25 - June 30 as part of the 13th annual national campaign to encourage voluntary HIV counseling and
Pfizer Receives Approvable Letter From FDA For Maraviroc: Business Wire - June 21, 2007; NEW YORK -- Pfizer announced today the U.S. Food and Drug Administration ( FDA ) issued an approvable letter for maraviroc, which is under review as a therapy for treatment-experienced patients infected with CCR5-tropic HIV-1. We continue our discussions with the FDA to address outstanding questions and finalize the pr
Aethlon Medical Discloses Strategy to Commercialize Hemopurifier(R) in India: Business Wire - June 21, 2007; SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that it will pursue the commercialization of its 1st generation Hemopurifier(R) in India during the course of the next year. The strategy to initiate commercialization in India corresponds with Aethlon s international objectives and will parallel the compa
First Ad35-Based HIV-1 Vaccine Enters Phase I Clinical Trial at the NIH: Business Wire - June 21, 2007; GAITHERSBURG, Md. -- GenVec, Inc. (Nasdaq:GNVC), announced today that the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has begun a Phase I clinical trial to test a novel vaccine known as Ad35HIV-EnvA to prevent HIV-1
Panacos Announces Substantial Antiviral Response in Bevirimat 250 mg Cohort, Data Support Further Dose Escalation in Phase 2b Study: Company to Hold a Conference Call at 5:00 p.m. EDT Today: Business Wire - June 20, 2007; WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced preliminary results from the 250 mg cohort of a Phase 2b study of bevirimat (PA-457) in patients failing HIV therapy due to drug resist
Interview of the First Lady by Kiran Chetry, CNN's American Morning International News Desks/Health Editors: Business Wire - June 20, 2007; WASHINGTON -- The Map Room 7:30 A.M. EDT Q Thanks so much, and thanks to everyone for joining us once again. It certainly is a special treat because I m joined now by First Lady Laura Bush. Thanks so much for your time and thanks so much for agreeing to appear on our show this morning. You certainly have a busy schedul
Profectus BioSciences, Inc. Announces NIH Grant: Small Business Innovative Research (SBIR) Grant from Division of AIDS Awarded to Expand Vaccine Approaches: Business Wire - June 19, 2007; BALTIMORE -- Profectus BioSciences, Inc., a biotechnology company that develops preventative and therapeutic technologies to reduce the morbidity and mortality caused by viral diseases, today announced the award of an approximately $300,000 Phase 1 Small Business Innovative Research (SBIR) grant from the Division of AI
Remarks by the First Lady in a Roundtable Discussion at Howard University's Center for Infectious Disease Management and Research: Business Wire - June 19, 2007; WASHINGTON -- Howard University Hospital Washington, D.C. MRS. BUSH: Well, I got to meet Dr. Maxwell when she was at the White House on World AIDS Day, where we talked about different programs that were going on in the United States and programs that were going on globally that address AIDS, programs that are funded in
Health Benchmarks(R) Manuscript Ranked Number 5 in the Top 10 Full Text Downloads from AIDS Care: Considerable Achievement Given the Number of Influential Articles Published in AIDS Care: Business Wire - June 18, 2007; WOODLAND HILLS, Calif. -- Health Benchmarks(R), Inc. (HBI) published a study of more than 2,100 patients diagnosed with HIV who were newly started on a fixed dose combination drug versus its components taken as separate pills. Findings from the study demonstrated that medication adherence was three times greater among
Geron Increases Stake in TA Therapeutics Joint Venture: Joint Venture Company is Working Toward Filing of IND for Small Molecule Compound to Treat HIV/AIDS: Business Wire - June 18, 2007; MENLO PARK, Calif. & HONG KONG -- Geron Corporation (Nasdaq: GERN) and the Biotechnology Research Corporation (BRC) of Hong Kong today announced that Geron has increased its stake in their joint venture entity, TA Therapeutics Limited (TAT), from 50% ownership to 75% ownership. TAT is a Hong Kong company that c
Medoctor, Inc. Partners With WHO: Business Wire - June 14, 2007; NAPA, Calif. -- Medoctor, Inc., has formed a partnership with the World Health Organization (WHO) called Sharing Healthcare Intellectual Property for Development (SHIPD). Other partners are the UK National Health Service and Informa Ltd. WHO announced the partnership at the World Health Assembly in May. The WHO has
Dole Food Company Honored by the Global Business Coalition on HIV/AIDS: Company's Efforts To Fight Tuberculosis (TB) Recognized: Business Wire - June 14, 2007; WESTLAKE VILLAGE, Calif. -- Dole Food Company, Inc. today announced that it has been awarded the Business Excellence on Tuberculosis Award by the Global Business Coalition on HIV/AIDS for its work to combat the disease in the Philippines . The award was presented Wednesday, June 13 during the 6th Annual GBC Awards for
Aethlon Medical Announces Issuance of Virus Treatment Patent: Business Wire - June 13, 2007; SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that Patent No. 7,226,429 has been issued to Aethlon Medical by the United States Patent and Trademark Office (USPTO). The patent, Method for Removal of Viruses from Blood by Lectin Affinity Hemodialysis, is integral to Aethlon s intellectual property port
L.A. High School Students Write and Produce a Provocative Play on the Heated Debate Revolving around Teen Pregnancy and HIV/AIDS: Students from Manual Arts High School collaborate with artistic director Susan Franklin Tanner to examine the various perspectives on teen pregnancy and the HIV/AIDS epidemic: Business Wire - June 12, 2007; Manual Arts High School: WHO: Manual Arts High School students with the support of director Susan Franklin Tanner. WHAT: A collaborative performance piece entitled Choices/Decisiones written and performed by Manual Arts High School students and directed by Susan Tanner. Student participants range in age from 14 to 16 a
OraSure Technologies Receives CE Mark for OraQuick ADVANCE(R) Rapid HIV Test: Approval Required for Sales in European Union: Business Wire - June 11, 2007; BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that it has received approval to affix the CE mark to its OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test, which is required to sell this product in the 27 countries that currently make up the European Union. The OraQuick ADVANCE(R) HIV test is
Remarks by the First Lady in a Roundtable Discussion on HIV/AIDS: Business Wire - June 11, 2007; SOFIA, Bulgaria -- Ministry of Health Sofia, Bulgaria 10:15 A.M. (Local) MRS. BUSH: I do want to thank you all for coming to talk about this. The United States government, as you know, has made a very large commitment to target HIV/AIDS, malaria, and tuberculosis in the hardest-hit countries, which, of course, are main
EU Officials Visit Imprisoned Medics and Families of HIV Infected Children in Libya: Business Wire - June 11 2007; WASHINGTON -- European Union External Relations Commissioner Benita Ferrero-Waldner and German Foreign Minister Frank-Walter Steinmeier today met with the Bulgarian nurses and a Palestinian doctor accused of infecting children with HIV in Libya . I admire the courage of the Bulgarian nurses and the Palestinian doctor,
Fact Sheet: The President's Achievements at the G-8 Summit, Heiligendamm, Germany: Business Wire - June 08, 2007; HEILIGENDAMM, Germany -- The President, In Collaboration With Other Leaders From The G-8 Nations, Took Action To Address A Broad Range Of Global Issues, Including: -- Launching a new global framework to address climate change, energy security, economic growth and sustainable development; -- Committing to partnering
Fact Sheet: A Record of Commitment to Africa - U.S. Plans to Substantially Increase Resources for Fight against Global HIV/AIDS</